Challenges in long-term mechanical circulatory support and biological replacement of the failing heart

Circulation Journal

Volumn 78, Issue 2, 2014, Pages 288-299

  Lala, Anuradha ^a,b   Joyce, Emer ^a   Groarke, John D ^a   Mehra, Mandeep R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Heart failure; Transplantation; Ventricular assist device

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; HEPARIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OCTREOTIDE; PEGINTERFERON; PREALBUMIN; RAPAMYCIN; RIBAVIRIN; TACROLIMUS;

AGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); CONGENITAL HEART DISEASE; ETHICS; GASTROINTESTINAL HEMORRHAGE; GRAFT REJECTION; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE; LEFT VENTRICULAR ASSIST DEVICE; MECHANICAL CIRCULATORY SUPPORT; ORGAN DONOR; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; RESTRICTIVE CARDIOMYOPATHY; REVIEW; RIGHT VENTRICULAR ASSIST DEVICE; THROMBOSIS; ASSISTED CIRCULATION; DEVICES; PROCEDURES;

ASSISTED CIRCULATION; HEART FAILURE; HEART TRANSPLANTATION; HUMANS;

EID: 84893004022     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1498     Document Type: Review

References (96)

1. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345: 1435-1443.
2. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al. The registry of the international society for heart and lung transplantation: Thirtieth official adult heart transplant report-2013; focus theme: Age. J Heart Lung Transplant 2013; 32: 951-964.
3. Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation 2010; 122: 173-183.
4. Stevenson LW. The urgent priority for transplantation is to trim the waiting list. J Heart Lung Transplant 2013; 32: 861-867.
5. Wever-Pinzon O, Drakos SG, Kfoury AG, Nativi JN, Gilbert EM, Everitt M, et al. Morbidity and mortality in heart transplant candidates supported with mechanical circulatory support: Is reappraisal of the current United network for organ sharing thoracic organ allocation policy justified? Circulation 2013; 127: 452-462.
6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 2013; 128: e240-e319, doi:10.1016/j.jacc.2013.05.019.
7. Mehra MR, Jessup M, Gronda E, Costanzo MR. Rationale and process: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates: 2006. J Heart Lung Transplant 2006; 25: 1001-1002.
8. Feldman D, Pamboukian SV, Teuteberg JJ, Birks E, Lietz K, Moore SA, et al. The 2013 International Society for Heart and Lung Transplantation guidelines for mechanical circulatory support: Executive summary. J Heart Lung Transplant 2013; 32: 157-187.
9. Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates: 2006. J Heart Lung Transplant 2006; 25: 1024-1042.
10. Alcorn T. China steps towards an ethical organ donor system. Lancet 2013; 382: 755.
11. Russo MJ, Davies RR, Sorabella RA, Martens TP, George I, Cheema FH, et al. Adult-age donors offer acceptable long-term survival to pediatric heart transplant recipients: An analysis of the United Network of Organ Sharing database. J Thorac Cardiovasc Surg 2006; 132: 1208-1212.
12. Bourge RC, Kirklin JK, Thomas K, Czerska B, Lee F, Kasper EK, et al. The emergence of co-morbid diseases impacting survival after cardiac transplantation, a ten year multi-institutional experience. J Heart Lung Transplant 2001; 20: 167-168.
13. Young JB, Hauptman PJ, Naftel DC, Ewald G, Aaronson K, Dec GW, et al. Determinants of early graft failure following cardiac transplantation, a 10-year, multi-institutional, multivariable analysis. J Heart Lung Transplant 2001; 20: 212.
14. Lietz K, John R, Mancini DM, Edwards NM. Outcomes in cardiac transplant recipients using allografts from older donors versus mortality on the transplant waiting list; Implications for donor selection criteria. J Am Coll Cardiol 2004; 43: 1553-1561.
15. Blanche C, Kamlot A, Blanche DA, Kearney B, Magliato KE, Czer LS, et al. Heart transplantation with donors fifty years of age and older. J Thorac Cardiovasc Surg 2002; 123: 810-815.
16. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914-956.
17. Grauhan O, Siniawski H, Dandel M, Leeart Matekuhl H, Knosalla C, Pasic M, et al. Coronary atherosclerosis of the donor heart: Impact on early graft failure. Eur J Cardiothorac Surg 2007; 32: 634-638.
18. Goland S, Czer LS, Kass RM, Siegel RJ, Mirocha J, De Robertis MA, et al. Use of cardiac allografts with mild and moderate left ventricular hypertrophy can be safely used in heart transplantation to expand the donor pool. J Am Coll Cardiol 2008; 51: 1214-1220.
19. Kuppahally SS, Valantine HA, Weisshaar D, Parekh H, Hung YY, Haddad F, et al. Outcome in cardiac recipients of donor hearts with increased left ventricular wall thickness. Am J Transplant 2007; 7: 2388-2395.
20. Kwong RY, Falk RH. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111: 122-124.
21. Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis 2010; 52: 347-361.
22. Miller AL, Falk RH, Levy BD, Loscalzo J. Clinical problem-solving: A heavy heart. N Engl J Med 2010; 363: 1464-1469.
23. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: An 8-year study. Ann Intern Med 2004; 140: 85-93.
24. Sharma N, Howlett J. Current state of cardiac amyloidosis. Curr Opin Cardiol 2013; 28: 242-248.
25. Varr BC, Liedtke M, Arai S, Lafayette RA, Schrier SL, Witteles RM. Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies. J Heart Lung Transplant 2012; 31: 325-331.
26. Swiecicki PL, Edwards BS, Kushwaha SS, Dispenzieri A, Park SJ, Gertz MA. Left ventricular device implantation for advanced cardiac amyloidosis. J Heart Lung Transplant 2013; 32: 563-568.
27. Frazier OH, Cohn WE. Continuous-flow total heart replacement device implanted in a 55-year-old man with end-stage heart failure and severe amyloidosis. Tex Heart Inst J 2012; 39: 542-546.
28. Estep JD, Bhimaraj A, Cordero-Reyes AM, Bruckner B, Loebe M, Torre-Amione G. Heart transplantation and end-stage cardiac amyloidosis: A review and approach to evaluation and management. Methodist Debakey Cardiovasc J 2012; 8: 8-16.
29. Davies RR, Russo MJ, Yang J, Quaegebeur JM, Mosca RS, Chen JM. Listing and transplanting adults with congenital heart disease. Circulation 2011; 123: 759-767.
30. Karamlou T, Hirsch J, Welke K, Ohye RG, Bove EL, Devaney EJ, et al. A United Network for Organ Sharing analysis of heart transplantation in adults with congenital heart disease: Outcomes and factors associated with mortality and retransplantation. J Thorac Cardiovasc Surg 2010; 140: 161-168.
31. Burchill LJ, Ross HJ. Heart transplantation in adults with end-stage congenital heart disease. Future Cardiol 2012; 8: 329-342.
32. Gelow JM, Song HK, Weiss JB, Mudd JO, Broberg CS. Organ allocation in adults with congenital heart disease listed for heart transplant: Impact of ventricular assist devices. J Heart Lung Transplant 2013; 32: 1059-1064.
33. Davies RR, Russo MJ, Morgan JA, Sorabella RA, Naka Y, Chen JM. Standard versus bicaval techniques for orthotopic heart transplantation: An analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg 2010; 140: 700-708, e1-e2.
34. Chiu P, Russo MJ, Davies RR, Addonizio LJ, Richmond ME, Chen JM. What is high risk? Redefining elevated pulmonary vascular resistance index in pediatric heart transplantation. J Heart Lung Transplant 2012; 31: 61-66.
35. Davies RR, Chen JM, Mosca RS. The Fontan procedure: Evolution in technique; attendant imperfections and transplantation for "failure". Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2011; 14: 55-66.
36. Lewden C, Salmon D, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: Emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005; 34: 121-130.
37. Calabrese LH, Albrecht M, Young J, McCarthy P, Haug M, Jarcho J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 2003; 348: 2323-2328.
38. Morgan JA, Bisleri G, Mancini DM. Cardiac transplantation in an HIV-1-infected patient. N Engl J Med 2003; 349: 1388-1389, author reply 1388-1389.
39. Uriel N, Jorde UP, Cotarlan V, Colombo PC, Farr M, Restaino SW, et al. Heart transplantation in human immunodeficiency virus-positive patients. J Heart Lung Transplant 2009; 28: 667-669.
40. Kumar MS, Sierka DR, Damask AM, Fyfe B, McAlack RF, Heifets M, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67: 1622-1629.
41. Roland ME, Stock PG. Solid organ transplantation is a reality for patients with HIV infection. Curr HIV/AIDS Rep 2006; 3: 132-138.
42. Ciuffreda D, Pantaleo G, Pascual M. Effects of immunosuppressive drugs on HIV infection: Implications for solid-organ transplantation. Transplant Int 2007; 20: 649-658.
43. Roland ME, Carlson LL, Frassetto LA, Stock PG. Solid organ transplantation: Referral, management, and outcomes in HIV-infected patients. AIDS Read 2006; 16: 664-668, 675-678.
44. Rajagopalan N, Hoopes CW, Rosenau J. Hepatitis C virus infection in heart transplantation: Is ventricular assist device therapy an option? Transplantation 2013; 96: e23-e24, doi:10.1097/TP. 0b013e31829c24a6.
45. Fagiuoli S, Minniti F, Pevere S, Farinati F, Burra P, Livi U, et al. HBV and HCV infections in heart transplant recipients. J Heart Lung Transplant 2001; 20: 718-724.
46. Fong TL, Hou L, Hutchinson IV, Cicciarelli JC, Cho YW. Impact of hepatitis C infection on outcomes after heart transplantation. Transplantation 2009; 88: 1137-1141.
47. Lee I, Localio R, Brensinger CM, Blumberg EA, Lautenbach E, Gasink L, et al. Decreased post-transplant survival among heart transplant recipients with pre-transplant hepatitis C virus positivity. J Heart Lung Transplant 2011; 30: 1266-1274.
48. Haji SA, Starling RC, Avery RK, Mawhorter S, Tuzcu EM, Schoenhagen P, et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 2004; 23: 277-283.
49. Wang BY, Chang HH, Chen IM, Shih CC, Yang AH. Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient. Ann Thorac Surg 2010; 89: 1645-1647.
50. Fagiuoli S, Cooper DK, Zuhdi N. Hepatitis C status of heart transplant recipients. Clin Transplant 1998; 12: 5-10.
51. Fagiuoli S, Pevere S, Minniti F, Livi U, Caforio AL, Naccarato R, et al. Natural leukocyte interferon alfa for the treatment of chronic viral hepatitis in heart transplant recipients. Transplantation 2003; 75: 982-986.
52. Durante-Mangoni E, Ragone E, Pinto D, Iossa D, Covino FE, Maiello C, et al. Outcome of treatment with pegylated interferon and ribavirin in heart transplant recipients with chronic hepatitis C. Transplant Proc 2011; 43: 299-303.
53. Kim EY, Ko HH, Yoshida EM. A concise review of hepatitis C in heart and lung transplantation. Can J Gastroenterol 2011; 25: 445-448.
54. Uber PA, Mehra MR. Induction therapy in heart transplantation: Is there a role? J Heart Lung Transplant 2007; 26: 205-209.
55. Higgins R, Kirklin JK, Brown RN, Rayburn BK, Wagoner L, Oren R, et al. To induce or not to induce: Do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? J Heart Lung Transplant 2005; 24: 392-400.
56. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241-2251.
57. Peura JL, Colvin-Adams M, Francis GS, Grady KL, Hoffman TM, Jessup M, et al. Recommendations for the use of mechanical circulatory support: Device strategies and patient selection: A scientific statement from the American Heart Association. Circulation 2012; 126: 2648-2667.
58. Mancini DM, Beniaminovitz A, Levin H, Catanese K, Flannery M, DiTullio M, et al. Low incidence of myocardial recovery after left ventricular assist device implantation in patients with chronic heart failure. Circulation 1998; 98: 2383-2389.
59. Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: Implications for patient selection. Circulation 2007; 116: 497-505.
60. Wilson SR, Mudge GH Jr, Stewart GC, Givertz MM. Evaluation for a ventricular assist device: Selecting the appropriate candidate. Circulation 2009; 119: 2225-2232.
61. Oz MC, Goldstein DJ, Pepino P, Weinberg AD, Thompson SM, Catanese KA, et al. Screening scale predicts patients successfully receiving long-term implantable left ventricular assist devices. Circulation 1995; 92: II169-III173.
62. Deng MC, Loebe M, El-Banayosy A, Gronda E, Jansen PG, Vigano M, et al. Mechanical circulatory support for advanced heart failure: Effect of patient selection on outcome. Circulation 2001; 103: 231-237.
63. Holman WL, Kormos RL, Naftel DC, Miller MA, Pagani FD, Blume E, et al. Predictors of death and transplant in patients with a mechanical circulatory support device: A multi-institutional study. J Heart Lung Transplant 2009; 28: 44-50.
64. Matthews JC, Koelling TM, Pagani FD, Aaronson KD. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. J Am Coll Cardiol 2008; 51: 2163-2172.
65. Fitzpatrick JR 3rd, Frederick JR, Hsu VM, Kozin ED, O'Hara ML, Howell E, et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. J Heart Lung Transplant 2008; 27: 1286-1292.
66. Kavarana MN, Pessin-Minsley MS, Urtecho J, Catanese KA, Flannery M, Oz MC, et al. Right ventricular dysfunction and organ failure in left ventricular assist device recipients: A continuing problem. Ann Thorac Surg 2002; 73: 745-750.
67. Schenk S, McCarthy PM, Blackstone EH, Feng J, Starling RC, Navia JL, et al. Duration of inotropic support after left ventricular assist device implantation: Risk factors and impact on outcome. J Thorac Cardiovasc Surg 2006; 131: 447-454.
68. Morgan JA, John R, Lee BJ, Oz MC, Naka Y. Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant mortality. Ann Thorac Surg 2004; 77: 859-863.
69. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant 2013; 32: 141-156.
70. Drakos SG, Janicki L, Horne BD, Kfoury AG, Reid BB, Clayson S, et al. Risk factors predictive of right ventricular failure after left ventricular assist device implantation. Am J Cardiol 2010; 105: 1030-1035.
71. Fukamachi K, McCarthy PM, Smedira NG, Vargo RL, Starling RC, Young JB. Preoperative risk factors for right ventricular failure after implantable left ventricular assist device insertion. Ann Thorac Surg 1999; 68: 2181-2184.
72. Ochiai Y, McCarthy PM, Smedira NG, Banbury MK, Navia JL, Feng J, et al. Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: Analysis of 245 patients. Circulation 2002; 106: I198-I202.
73. Dang NC, Topkara VK, Mercando M, Kay J, Kruger KH, Aboodi MS, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure. J Heart Lung Transplant 2006; 25: 1-6.
74. Santambrogio L, Bianchi T, Fuardo M, Gazzoli F, Veronesi R, Braschi A, et al. Right ventricular failure after left ventricular assist device insertion: Preoperative risk factors. Interact Cardiovasc Thorac Surg 2006; 5: 379-382.
75. Genovese EA, Dew MA, Teuteberg JJ, Simon MA, Kay J, Siegenthaler MP, et al. Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation. Ann Thorac Surg 2009; 88: 1162-1170.
76. Pagani FD, Miller LW, Russell SD, Aaronson KD, John R, Boyle AJ, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009; 54: 312-321.
77. Islam S, Cevik C, Madonna R, Frandah W, Islam E, Nugent K. Left ventricular assist devices and gastrointestinal bleeding: A narrative review of case reports and case series. Clin Cardiol 2013; 36: 190-200.
78. Demirozu ZT, Radovancevic R, Hochman LF, Gregoric ID, Letsou GV, Kar B, et al. Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant 2011; 30: 849-853.
79. Aggarwal A, Pant R, Kumar S, Sharma P, Gallagher C, Tatooles AJ, et al. Incidence and management of gastrointestinal bleeding with continuous flow assist devices. Ann Thorac Surg 2012; 93: 1534-1540.
80. Loscalzo J. From clinical observation to mechanism: Heyde's syndrome. N Engl J Med 2012; 367: 1954-1956.
81. Letsou GV, Shah N, Gregoric ID, Myers TJ, Delgado R, Frazier OH. Gastrointestinal bleeding from arteriovenous malformations in patients supported by the Jarvik 2000 axial-flow left ventricular assist device. J Heart Lung Transplant 2005; 24: 105-109.
82. Suarez J, Patel CB, Felker GM, Becker R, Hernandez AF, Rogers JG. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. Circ Heart Fail 2011; 4: 779-784.
83. Crow S, Chen D, Milano C, Thomas W, Joyce L, Piacentino V 3rd, et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg 2010; 90: 1263-1269, discussion 1269.
84. Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol 2009; 53: 2162-2167.
85. Wever-Pinzon O, Selzman CH, Drakos SG, Saidi A, Stoddard GJ, Gilbert EM, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. Circ Heart Fail 2013; 6: 517-526.
86. Holman WL, Pamboukian SV, McGiffin DC, Tallaj JA, Cadeiras M, Kirklin JK. Device related infections: Are we making progress? J Card Surg 2010; 25: 478-483.
87. Hannan MM, Husain S, Mattner F, Danziger-Isakov L, Drew RJ, Corey GR, et al. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. J Heart Lung Transplant 2011; 30: 375-384.
88. Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 2012; 125: 3191-3200.
89. Mehra MR, Stewart GC, Uber PA. The vexing problem of thrombosis in long-term mechanical circulatory support. J Heart Lung Transplant 2014; 33: 1-11.
90. Starling RC, Naka Y, Boyle AJ, Gonzalez-Stawinski G, John R, Jorde U, et al. Results of the post-U.S. Food and Drug Administrationapproval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: A prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2011; 57: 1890-1898.
91. Boyle AJ, Russell SD, Teuteberg JJ, Slaughter MS, Moazami N, Pagani FD, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: Analysis of outpatient anti-coagulation. J Heart Lung Transplant 2009; 28: 881-887.
92. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, Reichenspurner H, Angelini A, Berry G, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2011; 30: 252-269.
93. Mehra MR. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 2006; 6: 1248-1256.
94. Mehra MR, Crespo-Leiro MG, Dipchand A, Ensminger SM, Hiemann NE, Kobashigawa JA, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy: 2010. J Heart Lung Transplant 2010; 29: 717-727.
95. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. J Heart Lung Transplant 2012; 31: 117-126.
96. Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, et al; International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth official adult heart transplant report-2013; focus theme: Age. J Heart Lung Transplant 2013; 32: 951-964.